Sickle cell disease warps red blood cells into rigid, crescent-shaped cells that get stuck in blood vessels, blocking oxygen delivery throughout the body. A single genetic mutation is responsible: one amino acid swap on the surface of hemoglobin, the protein that carries oxygen in your blood. That tiny change triggers a chain reaction that damages nearly every organ over time. Normal red blood cells live about 120 days, but sickled cells survive only 10 to 20 days, leaving the body in a constant state of anemia and repair.
How Red Blood Cells Change Shape
Hemoglobin is the molecule inside red blood cells that picks up oxygen in the lungs and delivers it to tissues. In sickle cell disease, the body produces an altered version called hemoglobin S. The difference comes down to one spot on the protein’s surface where a water-attracting building block (glutamic acid) has been replaced by a water-repelling one (valine).
When hemoglobin S releases its oxygen in the tissues, that exposed sticky patch causes hemoglobin molecules to latch onto each other and form long, stiff fibers inside the cell. These fibers stretch the normally soft, disc-shaped red blood cell into a rigid sickle or crescent. The process reverses when the cell picks up oxygen again in the lungs, but repeated cycles of sickling and unsickling eventually damage the cell membrane permanently. The cell becomes irreversibly sickled, and the body destroys it far earlier than normal.
What Happens During a Pain Crisis
The hallmark of sickle cell disease is the vaso-occlusive crisis, commonly called a pain crisis. It starts when sickled red blood cells stick to the walls of small blood vessels. But these cells don’t act alone. The blood vessel lining releases a sticky protein that attracts platelets, and those platelets form clusters that trap even more red blood cells. The result is a growing blockage that cuts off blood flow to nearby tissue.
This triggers intense inflammation. The body releases inflammatory signals that make vessel walls even stickier, which draws in white blood cells and worsens the blockage. The pain can strike almost anywhere: the chest, back, arms, legs, or abdomen. Episodes can last hours to days and often require hospital-level pain management. Some people experience a few crises per year, while others deal with them monthly. Triggers include dehydration, cold temperatures, stress, and infection.
Damage to the Spleen and Immune System
The spleen is one of the first organs to suffer. It filters blood and helps fight infections, but its narrow blood vessels make it especially vulnerable to blockages by sickled cells. Repeated episodes of blocked blood flow scar and shrink the spleen until it stops working entirely, a process called autosplenectomy. In many children with sickle cell disease, the spleen is functionally gone by early childhood.
Losing the spleen has serious consequences for immunity. The spleen is your primary defense against certain types of bacteria that coat themselves in a protective capsule, including the bacteria responsible for pneumococcal pneumonia, certain types of meningitis, and some ear and sinus infections. Without a functioning spleen, these infections can become life-threatening within hours. This is why children with sickle cell disease receive extra vaccinations and often take daily preventive antibiotics.
Lung Complications
Acute chest syndrome is one of the most dangerous complications. It occurs when sickled cells block blood flow in the lungs, sometimes triggered by a viral or bacterial infection. In children, infection is the most common cause. Symptoms closely resemble pneumonia: chest pain, coughing, difficulty breathing, and fever. It can escalate quickly and is a leading cause of hospitalization and death in people with sickle cell disease.
Over time, repeated episodes of acute chest syndrome can scar the lungs and raise blood pressure in the blood vessels that supply them. This chronic lung damage makes each subsequent episode more dangerous.
Brain and Cognitive Effects
Sickle cell disease poses a significant threat to the brain, especially in children. About 40% of children with sickle cell disease develop silent brain infarcts (small areas of brain damage from blocked blood flow) by age 18. These are called “silent” because they don’t cause the obvious symptoms of a full stroke, like sudden weakness or slurred speech. Instead, they quietly erode cognitive function, affecting memory, attention, processing speed, and academic performance.
Full strokes also occur at much higher rates than in the general population, even in young children. Regular screening with transcranial Doppler ultrasound, which measures blood flow velocity in the brain, can identify children at high risk for stroke so that preventive treatment can begin.
Kidney Damage Over Time
The kidneys are particularly vulnerable because their internal structure relies on the same kind of small, winding blood vessels that sickled cells tend to block. One of the earliest signs of kidney involvement is a reduced ability to concentrate urine, which means the kidneys can’t hold onto water efficiently. This shows up as frequent urination and a higher risk of dehydration, which in turn can trigger more sickling.
In childhood and adolescence, the kidneys often compensate by working harder than normal, pushing blood through at elevated rates. But this overwork takes a toll. About 24% of adults with sickle cell disease develop chronic kidney disease, according to a study of over 2,300 adults. As the disease progresses, the kidneys shrink, scar, and gradually lose function. Some patients eventually require dialysis or transplantation.
The Constant Toll of Anemia
Because sickled red blood cells are destroyed six to twelve times faster than normal cells, the bone marrow works overtime to replace them but can never fully keep up. The result is chronic anemia, meaning the blood carries less oxygen than the body needs. This produces persistent fatigue, shortness of breath during exertion, dizziness, and a faster heart rate as the heart tries to compensate by pumping harder.
Children with sickle cell disease often grow more slowly than their peers and may reach puberty later. In adults, chronic anemia contributes to reduced exercise tolerance and can strain the heart over decades, sometimes leading to heart enlargement or heart failure.
How It’s Detected
In the United States, every newborn is screened for sickle cell disease through a simple blood test, typically a heel prick done in the first day or two of life. Sickle cell disease has been on the federal Recommended Uniform Screening Panel since 2006, and all 50 states include it in their newborn screening programs. Early detection matters because starting preventive measures, like penicillin and vaccinations, in infancy dramatically reduces the risk of life-threatening infections.
Treatment Options Today
For decades, management focused on preventing and treating crises: staying hydrated, avoiding triggers, taking a medication called hydroxyurea that boosts production of fetal hemoglobin (a form of hemoglobin that doesn’t sickle), and receiving blood transfusions when needed. Fetal hemoglobin is the type babies produce before birth, and higher levels of it in the blood interfere with the clumping process that causes sickling.
In December 2023, the FDA approved two gene therapies that offer the possibility of a lasting fix. The first, Casgevy, is the first approved therapy to use CRISPR gene-editing technology. A patient’s own blood stem cells are removed, edited to reactivate fetal hemoglobin production, and transplanted back. The increased fetal hemoglobin prevents red blood cells from sickling. The second, Lyfgenia, uses a different approach: a modified virus delivers a new gene that instructs stem cells to produce a hemoglobin variant that functions like normal adult hemoglobin, reducing the risk of sickling and blood vessel blockages.
Both therapies require intensive preparation, including chemotherapy to clear existing bone marrow before the modified stem cells are transplanted back. Recovery takes weeks to months in a medical center. These treatments are currently expensive and available only at specialized centers, but they represent a fundamental shift from managing symptoms to correcting the underlying problem in the blood.